All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to Steering Committee member Arnon Nagler, Tel Aviv University, Tel Aviv, IL, about the role of the microbiota in GvHD. We asked, How should antibiotics be administered in transplant patients to reduce GvHD?
How should antibiotics be administered in transplant patients to reduce GvHD?
The gut microbiome has been extensively investigated in the last few decades, and this research has highlighted the importance of the diversity of the intestinal microbiota, along with maintaining the integrity of the epithelial cells of the gut. During bone marrow transplant, dysbiosis can be triggered and the intestinal epithelium damaged as a result of reduced food intake, radiation, and antibiotic use. This causes a reduction in the population of microbes which have a protective effect in GvHD.
Subscribe to get the best content related to GvHD delivered to your inbox